LEESBURG, Va.–(BUSINESS WIRE)–K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced the debut of a breakthrough injectable polymer technology at the 9th Annual Spine Arthroplasty Society (SAS) Meeting in London, England. Preliminary testing indicates the polymer may have many different applications for treating a variety of spinal disorders.
K2M obtained the worldwide exclusive rights for all spinal applications of this material through an agreement with Promethean Surgical Devices, Inc. (PSD) in November 2008. In furtherance of K2M’s goal to be a market leader in the complex spine market, the injectable polymer will serve as a platform for the development of new implantable technologies. The material has demonstrated unique properties that could lead to the development of a new treatment modality and earlier intervention to address multiple pathologies, such as spinal nucleus replacement, or micro-access surgical approaches for annular decompression and repair.
“K2M is excited to be a part of the rapidly expanding biomaterials sector of the spine industry that has the potential to radically improve surgery outcome by providing technologies for earlier patient intervention,” stated Eric Major, K2M’s President and CEO. “The debut of this injectable polymer reaffirms K2M’s commitment to our new Biomaterials R&D Division and demonstrates investment in our near and long term pipeline of differentiated technologies.”
